Glaukos Corp. (GKOS)
NYSE:GKOS
Want to see GKOS full AI Analyst Report?
GKOS Stock Chart & Stats
$124.79
$1.50(0.96%)
At close: 4:00 PM EST
$124.79
$1.50(0.96%)
Day’s Range― - ―
52-Week Range$73.16 - $148.11
Previous CloseN/A
Volume137.72K
Average Volume (3M)1.08M
Market Cap
$6.67B
Enterprise Value$6.07B
Total Cash (Recent Filing)$276.69M
Total Debt (Recent Filing)$103.06M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Aug 05, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.28
Shares Outstanding58,733,910
10 Day Avg. Volume1,620,799
30 Day Avg. Volume1,084,347
Financial Highlights & Ratios
PEG Ratio-1.87
Price to Book (P/B)9.84
Price to Sales (P/S)12.73
P/FCF Ratio-119.57
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue11.01
Enterprise Value/Gross Profit14.10
Enterprise Value/Ebitda-151.77
Forecast
1Y Price Target
$151.56Price Target Upside21.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.51
Revenue Forecast (FY)$630.78M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & GuidancESustained double-digit top-line growth and an upward guidance revision reflect durable commercial traction for procedural ophthalmic therapies. Strong revenue momentum supports investment in commercialization and R&D while improving the path to eventual operating leverage and scale economics.
High Gross Margin ProfilePersistently high gross margins indicate structurally advantaged product economics from proprietary implants and consumables. Such margin durability can absorb elevated opex for launches and support faster progress toward operating profitability as revenues scale and fixed-cost absorption improves.
Conservative Balance Sheet / LiquidityA sizable cash position and minimal leverage provide multi-quarter runway to fund commercial launches and pivotal programs without near-term refinancing risk. Conservative capital structure gives management flexibility to invest in payer access and international expansion while managing cash-burn variability.
Bears Say
Negative Cash FlowPersistent negative operating and free cash flow means the business still depends on existing liquidity or financing to sustain growth. Continued cash burn, even if reduced, raises execution risk if commercial ramps or regulatory milestones slip, potentially pressuring long-term funding needs.
Rising Operating ExpensesDeliberate increases in opex to support Epioxa and other launches amplify near-term profitability headwinds. If revenue ramps or payer adoption lag expectations, higher fixed costs could delay cash-flow breakeven and extend the period of negative returns for shareholders and pressure capital allocation choices.
Payer Access & Corneal Transition FrictionEpioxa commercialization faces structural access constraints during the misc-code period and procedural channel shifts, creating elongated reimbursement cycles. Such durable payer frictions and channel mix changes can depress early revenue predictability and increase commercial cost-to-serve during critical launch windows.
Glaukos News
GKOS FAQ
What was Glaukos Corp.’s price range in the past 12 months?
Glaukos Corp. lowest stock price was $73.16 and its highest was $148.11 in the past 12 months.
What is Glaukos Corp.’s market cap?
Glaukos Corp.’s market cap is $6.67B.
When is Glaukos Corp.’s upcoming earnings report date?
Glaukos Corp.’s upcoming earnings report date is Aug 05, 2026 which is in 61 days.
How were Glaukos Corp.’s earnings last quarter?
Glaukos Corp. released its earnings results on Apr 29, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.281 by $0.101.
Is Glaukos Corp. overvalued?
According to Wall Street analysts Glaukos Corp.’s price is currently Undervalued.
Does Glaukos Corp. pay dividends?
Glaukos Corp. does not currently pay dividends.
What is Glaukos Corp.’s EPS estimate?
Glaukos Corp.’s EPS estimate is -0.21.
How many shares outstanding does Glaukos Corp. have?
Glaukos Corp. has 58,733,910 shares outstanding.
What happened to Glaukos Corp.’s price movement after its last earnings report?
Glaukos Corp. reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.281. Following the earnings report the stock price went up 22.837%.
Which hedge fund is a major shareholder of Glaukos Corp.?
Currently, no hedge funds are holding shares in GKOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Glaukos Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$151.56 (21.45% Upside)
$151.56 (21.45% Upside)
Blogger Sentiment
Neutral
GKOS Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 319.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.1%
Last 30 Days ▲ 19.0%
Last 30 Days ▲ 19.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.26%
12-Months-Change
Fundamentals
Return on Equity
-26.46%
Trailing 12-Months
Asset Growth
-7.54%
Trailing 12-Months
Company Description
Glaukos Corp.
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
GKOS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong commercial execution and meaningful growth: record Q1 revenue (+41% reported), raised guidance, robust U.S. glaucoma performance driven by iDose TR, encouraging early commercial and access milestones for Epioxa (including CMS J-code and >100M covered lives), improved gross margin, and a deep clinical pipeline with clear regulatory timelines. Near-term challenges include payer adoption frictions for Epioxa during the miscellaneous J-code period, expected quarter-to-quarter volatility in Corneal Health during the Photrexa-to-Epioxa transition (notably a Q2 dip), potential international competitive and currency headwinds, modestly higher operating expenses to fund launches, and residual policy/LCD risk for interventional glaucoma. Overall, the positive commercial momentum, material guidance raise, margin accretion, and pipeline progress materially outweigh the near-term operational and access headwinds.View all GKOS earnings summariesGKOS Stock 12 Month Forecast
Average Price Target
$151.56
▲(21.45% Upside)
Technical Analysis
Integer Holdings
―
Ufp Technologies
―
Tandem Diabetes Care
―
LivaNova
―
Irhythm Technologies
―
Ownership Overview
3.92% Insiders
37.87% Mutual Funds
26.36% Other Institutional Investors
8.32% Public Companies and
Individual Investors